Thrivent Financial for Lutherans Makes New Investment in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Thrivent Financial for Lutherans acquired a new stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,355 shares of the company’s stock, valued at approximately $1,079,000.

Several other large investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its stake in shares of Allogene Therapeutics by 102.7% during the second quarter. Wells Fargo & Company MN now owns 10,790 shares of the company’s stock valued at $281,000 after purchasing an additional 5,468 shares during the period. Woodline Partners LP lifted its stake in Allogene Therapeutics by 1.8% in the second quarter. Woodline Partners LP now owns 684,755 shares of the company’s stock worth $17,858,000 after acquiring an additional 12,111 shares during the period. Invesco Ltd. lifted its stake in Allogene Therapeutics by 86.1% in the second quarter. Invesco Ltd. now owns 39,411 shares of the company’s stock worth $1,028,000 after acquiring an additional 18,236 shares during the period. Metropolitan Life Insurance Co NY lifted its stake in Allogene Therapeutics by 126,900.0% in the second quarter. Metropolitan Life Insurance Co NY now owns 19,050 shares of the company’s stock worth $497,000 after acquiring an additional 19,035 shares during the period. Finally, Millennium Management LLC lifted its stake in Allogene Therapeutics by 78.6% in the second quarter. Millennium Management LLC now owns 505,295 shares of the company’s stock worth $13,178,000 after acquiring an additional 222,330 shares during the period. 75.10% of the stock is owned by hedge funds and other institutional investors.

In other Allogene Therapeutics news, CMO Rafael Amado sold 11,507 shares of the firm’s stock in a transaction dated Friday, October 1st. The stock was sold at an average price of $24.35, for a total value of $280,195.45. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Owen N. Witte sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 9th. The stock was sold at an average price of $25.54, for a total value of $127,700.00. Following the completion of the transaction, the director now directly owns 221,182 shares in the company, valued at $5,648,988.28. The disclosure for this sale can be found here. Company insiders own 26.30% of the company’s stock.

Shares of NASDAQ:ALLO opened at $18.67 on Thursday. Allogene Therapeutics, Inc. has a 1-year low of $12.90 and a 1-year high of $39.12. The business has a fifty day moving average price of $19.95 and a 200-day moving average price of $22.83. The company has a market capitalization of $2.66 billion, a PE ratio of -9.93 and a beta of 0.79.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Thursday, November 4th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.01). The firm had revenue of $0.05 million during the quarter. During the same quarter in the prior year, the firm earned ($0.52) earnings per share. On average, analysts expect that Allogene Therapeutics, Inc. will post -1.97 EPS for the current year.

ALLO has been the subject of a number of research analyst reports. Raymond James raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $36.00 price target for the company in a research note on Thursday, September 23rd. B. Riley dropped their price target on Allogene Therapeutics from $52.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 6th. They noted that the move was a valuation call. Bank of America dropped their price target on Allogene Therapeutics from $41.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, October 8th. Cowen started coverage on Allogene Therapeutics in a report on Wednesday, October 20th. They issued an “outperform” rating for the company. Finally, Stifel Nicolaus downgraded Allogene Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $44.00 to $18.00 in a report on Friday, October 8th. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Allogene Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $36.14.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.

Featured Story: Elliott Wave Theory

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.